BACKGROUND: Hematologic markers, such as the neutrophil-to-lymphocyte ratio (NLR), characterize the inflammatory response to cancer and are associated with poorer survival in various malignancies. We evaluate the effect of pretreatment NLR on overall survival (OS) in patients with head and neck squamous cell carcinoma (HNSCC). METHODS: Using multiple databases, a systematic search for articles evaluating the effect of NLR on OS in patients with HNSCC was performed. An inverse variation, random-effects model was used to analyze the data. RESULTS: A total of 24 of 241 articles, including 6479 patients, were analyzed. The combined hazard ratio for OS in patients with an elevated NLR (range 2.04-5) was 1.78 (confidence interval [CI] 1.53-2.07; P < .0001). The hazard ratios for site-specific cancer: oral cavity 1.56 CI 1.23-1.98 (P < .001), nasopharynx 1.66 CI 1.35-2.04 (P < .001), larynx 1.55 CI 1.26-1.92 (P < .001), and hypopharynx 2.36 CI 1.54-3.61 (P < .001). CONCLUSION: An elevated NLR is predictive of poorer OS in patients with HNSCC.
BACKGROUND: Hematologic markers, such as the neutrophil-to-lymphocyte ratio (NLR), characterize the inflammatory response to cancer and are associated with poorer survival in various malignancies. We evaluate the effect of pretreatment NLR on overall survival (OS) in patients with head and neck squamous cell carcinoma (HNSCC). METHODS: Using multiple databases, a systematic search for articles evaluating the effect of NLR on OS in patients with HNSCC was performed. An inverse variation, random-effects model was used to analyze the data. RESULTS: A total of 24 of 241 articles, including 6479 patients, were analyzed. The combined hazard ratio for OS in patients with an elevated NLR (range 2.04-5) was 1.78 (confidence interval [CI] 1.53-2.07; P < .0001). The hazard ratios for site-specific cancer: oral cavity 1.56 CI 1.23-1.98 (P < .001), nasopharynx 1.66 CI 1.35-2.04 (P < .001), larynx 1.55 CI 1.26-1.92 (P < .001), and hypopharynx 2.36 CI 1.54-3.61 (P < .001). CONCLUSION: An elevated NLR is predictive of poorer OS in patients with HNSCC.
Authors: Cristina Valero; Daniella K Zanoni; Marlena R McGill; Ian Ganly; Luc G T Morris; Miquel Quer; Jatin P Shah; Richard J Wong; Xavier León; Snehal G Patel Journal: Cancer Date: 2019-12-06 Impact factor: 6.860
Authors: Cathelijn E M Aarts; Ida H Hiemstra; Eelke P Béguin; Arjan J Hoogendijk; Souhailla Bouchmal; Michel van Houdt; Anton T J Tool; Erik Mul; Machiel H Jansen; Hans Janssen; Floris P J van Alphen; Jan-Paul de Boer; Charlotte L Zuur; Alexander B Meijer; Timo K van den Berg; Taco W Kuijpers Journal: Blood Adv Date: 2019-11-26
Authors: Mario Sánchez-Canteli; Luis Juesas; Esther Redin; Alfonso Calvo; Fernando López; Aurora Astudillo; Luis M Montuenga; Juana M García-Pedrero; Juan P Rodrigo Journal: Cancers (Basel) Date: 2021-04-25 Impact factor: 6.639
Authors: Piergiorgio Gaudioso; Daniele Borsetto; Giancarlo Tirelli; Margherita Tofanelli; Fiordaliso Cragnolini; Anna Menegaldo; Cristoforo Fabbris; Gabriele Molteni; Daniele Marchioni; Piero Nicolai; Paolo Bossi; Andrea Ciorba; Stefano Pelucchi; Chiara Bianchini; Simone Mauramati; Marco Benazzo; Vittorio Giacomarra; Roberto Di Carlo; Mantegh Sethi; Jerry Polesel; Jonathan Fussey; Paolo Boscolo-Rizzo Journal: Support Care Cancer Date: 2021-01-29 Impact factor: 3.359
Authors: Pierluigi Mariani; Diana Russo; Marco Maisto; Giuseppe Troiano; Vito Carlo Alberto Caponio; Marco Annunziata; Luigi Laino Journal: J Oral Pathol Med Date: 2021-12-09 Impact factor: 3.539